NCT05543317View on ClinicalTrials.gov

68Ga-FAPI-RGD PET/CT for Dual Integrin αvβ3 and FAP-targeted Imaging in Patients With Various Types of Cancer and Compared With 18F-FDG

NACompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Tumor, SolidPositron-Emission Tomography
Interventions
DIAGNOSTIC_TEST

18F-FDG PET/CT, 68Ga-FAPI-RGD PET/CT

Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-RGD, and undergo PET/CT imaging within the specified time. A part of participants will undergo additional 68Ga-FAPI-46 PET/CT for comparison.

Trial Locations (1)

361000

The First Affiliated Hospital of Xiamen University, Xiamen

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER